J2K Bio Announces 200 Won Cash Dividend Per Share to "Enhance Shareholder Value"

J2K Bio announced on the 13th that despite a one-time increase in expenses and a decrease in profitability due to last year's listing, it has decided on a cash dividend of 200 KRW per share. The dividend yield for this payout is 2.16%, with a total dividend amount of 1.14656 billion KRW. Through this, J2K Bio plans to enhance shareholder value and strengthen long-term corporate credibility.

Last year, J2K Bio recorded consolidated sales of 33.12918 billion KRW, marking a 16.4% growth compared to the same period the previous year. Operating profit remained positive at 3.64935 billion KRW. However, profits decreased compared to the previous year due to one-time expenses such as investments in the clinical center and special bonuses related to the listing. Additionally, a non-operating loss from a SPAC merger amounting to approximately 5 billion KRW resulted in a net loss of 2.30727 billion KRW for the period.

This year, J2K Bio plans to expand cooperation with large corporations based on its existing stable transaction structure centered on OEM companies and numerous indie brands. A sharp increase in sales is expected through diversification of the sales structure, and profitability is also projected to improve significantly.

J2K Bio intends to further strengthen its market competitiveness by developing various new raw materials using its own collection of about 1,000 proprietary strains. Alongside this, the company is building a library based on its proprietary strains and developing platform technologies to apply new raw materials to various new products.

A J2K Bio representative stated, "Although profits decreased last year due to temporary costs related to the listing despite sales growth, we decided on a cash dividend to increase shareholder value. Starting this year, steady performance growth is expected based on a stable business structure, so we will ensure continuous dividends."

He added, "We will expand the development of new raw materials and their application to new products based on platform technology using our collection of about 1,000 proprietary strains. We plan to advance the platform technology accumulated through the cosmetics business and expand into the food and pharmaceutical sectors."

This content was produced with the assistance of AI translation services.